Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
Comment: Fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.06.19
Views: 927

Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands

Prof Anton Hagenbeek comments on Dr Kirsten Fischer's talk on fixed-duration venetoclax plus obinutuzumab in patients with previously untreated chronic lymphocytic leukaemia (CLL) and comorbidities at the 2019 European Hematology Association (EHA) Annual Meeting.

Dr Fischer's study was found to improve progression free survival and minimal residual disease negativity in these patients.

Dr Hagenbeek remarks that he expects the treatment to be approved by the FDA and EMA in the years to come - making it the new standard of care for elderly patients with comorbidities and CLL.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content. 

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation